TY  - CHAP
M1  - Book, Section
TI  - Appendix E - Example Care Plan with Missing Data
A1  - Matthias, Kathryn R.
A1  - Katz, Michael D.
PY  - 2023
T2  - Pharmacotherapy Principles and Practice Study Guide, 6e
AB  - Table  Graphic  Jump  Location|Download  (.pdf)|PrintMock  Patient  Name:Preferred  Pronoun:Mock  MRN:Age:Sex  Assigned  at  Birth:Height:Race:Gender:Weight:Ethnicity:Preferred  Pharmacy:PCP:Insurance:Allergies/Intolerances/ADRsHPI,  FH,  SH,  Social  Determinants  of  Health,  Health  Literacy□  No  known  drug  allergies/ADRs□  Not  known/inadequate  informationDrugReactionAdditional  Information:Prioritized  Medical  Problem  ListMedication  Profile123456Health  Maintenance:PMH  with  no  therapy  needed:Inadequate  Database:Vital  Signs,  Laboratory  Data,  and  Diagnostic  Test  ResultsNormal  Range  or  UnitsDayTodayWeightlbs  (kg)TemperatureoCBlood  PressuremmHgPulseRespiratory  RateNa135–145  mEq/L  (135–145  mmol/L)K3.3–4.9  mEq/L  (3.3–4.9  mmol/L)Cl97–110  mEq/L  (97–110  mmol/L)CO2/HCO322–26  mEq/L  (22–26  mmol/L)BUN8–25  mg/dl  (2.9–8.9  mmol/L)Serum  Creatinine  (adult)male  0.7–1.3  mg/dl;  female  0.6–1.1  mg/dl  (male  62–115  m  µmol/L;  female  53–97  µmol/L)Creatinine  Clearance  (adult)85–135  mL/min  (1.42–2.25  mL/s)Glucose  (fasting)65–109  mg/dl  (3.6–6.0  mmol/L)Total  Ca8.6–10.3  mg/dl  (2.15–2.58  mmol/L)Mg1.3–2.2  mEq/L  (0.65–1.10  mmol/L)PO42.5–4.5  mg/dl  (0.81–1.45  mmol/L)Hemoglobinmale  13.8–17.2  g/dl;  female  12.1–15.1  g/dl  (male  138–172  g/L;  female  121–151  g/L)Hematocritmale  40.7–50.3%;  female  36.1–44.3%  (male  0.407–0.503;  female  0.361–0.443)MCV80.0–97.6  µm3  (80.0–97.6  fL)WBC4–10  ×  103/mm3  (4–10  ×  109/L)WBC  Differential%  polymorphonuclear  neutrophils  (PMN)/eosinophils/basophils/lymphocytes/monocytes/////  /  /  //  /  /  /Platelets140–440  ×  103/mm3  (140–440  ×  109/L)Albumin3.5–5  g/dl  (35–50  g/L)Bilirubin  (total)0.3–1.1  mg/dl  (5.13–18.80  µmol/L)Bilirubin  (direct)0–0.3  mg/dl  (0–5.1  µmol/L)AST11–47  IU/L  (0.18–0.78  µkat/L)ALT7–53  IU/L  (0.12–0.88  µkat/L)Alk  phos  (adult)38–126  IU/L  (0.13–2.10  µkat/L)PH7.35–7.45PO270–95  mmHg  (9.3–12.6  kPa)O2Saturation  (90–110%)PCO235–45  mmHg  (4.7–6.0  kPa)Urine  HCGAdditional  Notes:DRUG  THERAPY  PROBLEM  WORKSHEETType  of  ProblemPossible  CausesProblem  ListNotesCorrelation  between  drug  therapy  and  medical  problemsDrugs  without  obvious  medical  indicationsMedication(s)  unidentifiedUntreated  medical  conditionsNeed  for  additional  drug  therapyNew  medical  condition  requiring  new  drug  therapyChronic  disorder  requiring  continued  drug  therapyCondition  best  treated  with  combination  drug  therapyMay  develop  new  medical  condition  without  prophylactic  or  preventative  therapy  or  premedicationUnnecessary  drug  therapyMedication(s)  with  no  valid  indication  or  condition  is  better  treated  with  nondrug  therapyCondition  caused  by  accidental  or  intentional  ingestion  of  toxic  amount  of  drug(s)  or  chemicalsMedical  problem(s)  associated  with  use  of  or  withdrawal  from  alcohol,  drugs,  or  tobaccoTaking  multiple  drugs  when  single  agent  is  as  effectiveTaking  drug(s)  to  treat  an  avoidable  adverse  reaction  from  another  medicationAppropriate  drug  selectionCurrent  regimen  not  usually  as  effective  or  safe  as  other  choicesTherapy  not  individualized  to  patientWrong  drugMedical  problem  for  which  drug  is  not  effectivePatient  has  risk  factors  that  contraindicate  use  of  drugPatient  has  infection  with  organisms  resistant  to  drugPatient  refractory  to  current  drug  therapyTaking  combination  product  when  single  agent  appropriateDosage  form  inappropriate  or  medication  errorDrug  regimenPRN  use  not  appropriate  for  conditionRoute  of  administration/dosage  form/mode  of  administration  not  appropriate  for  current  conditionLength  or  course  of  therapy  not  appropriateDrug  therapy  altered  without  adequate  therapeutic  trialDose  or  interval  flexibility  not  appropriateDose  too  lowDose  or  frequency  too  low  to  produce  desired  response  in  this  patientSerum  drug  concentration  below  desired  goal  range  for  indicationTiming  of  antimicrobial  prophylaxis  not  appropriateMedication  not  stored  properly  or  medication  errorDose  too  highDose  or  frequency  too  high  for  this  patientSerum  drug  concentration  above  the  desired  goal  range  for  indicationDose  escalated  too  quicklyDose  or  interval  flexibility  not  appropriate  for  this  patientMedication  errorTherapeutic  duplicationReceiving  multiple  agents  without  added  benefitDrug  allergy/adverse  drug  eventsHistory  of  allergy  or  ADE  to  current  (or  chemically  related)  agentsAllergy  or  ADE  history  not  in  medical  recordsPatient  not  using  alert  for  severe  allergy  or  ADESymptoms  or  medical  problems  that  may  be  drug  inducedDrug  administered  too  rapidlyMedication  error,  actual  or  potentialInteractions  (drug-drug,  drug-disease,  drug-nutrient,  drug-laboratory  test)Effect  of  drug  altered  due  to  enzyme  induction/inhibition,  protein  binding  alterations,  or  pharmacodynamic  change  from  another  drug  patient  ...
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/10/10
UR  - ppp.mhmedical.com/content.aspx?aid=1198803008
ER  -